Navigation Links
FDA Fails to Consider Risks of Over-the-Counter Plan B
Date:4/23/2009

WASHINGTON, April 23 /PRNewswire-USNewswire/ -- Moira Gaul, Family Research Council's Director of Women's and Reproductive Health, released the following statement regarding the Obama Administration's decision to sell the morning-after-pill to 17-year-olds without a prescription.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO )

"The Obama Administration is permitting a judge to make a scientific decision as to the safety of the over-the-counter sale of Plan B. This decision places policy preferences before safety. The best interest of women's health is not advanced by these decisions. Reason, science, and compassion clearly are not the animating factors of the decision.

"In order for a drug to be sold over-the-counter, patients must be able to safely medicate themselves without medical supervision. Studies tracking the label comprehension for Plan B show poor awareness that Plan B is not a substitute for standard contraceptives. The FDA-approved label for Plan B gives no clear indication that repeated use of Plan B in a short period of time is not safe.

"FDA officials understood these safety concerns in 2006 and were not convinced that the label comprehension data for teens demonstrated that they could use Plan B safely. The FDA officials believed more data needed to be submitted.

"There is a real danger that Plan B may be given to women, especially sexually abused women and minors, under coercion or without their consent. Interaction with medical professionals is a major screening and defense mechanism for victims of sexual abuse. The availability of Plan B over-the-counter also bypasses the necessary routine medical care of sexually active girls and women, which is important for the screening of health conditions, and for providing screening for sexually t
'/>"/>

SOURCE Family Research Council
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Federal research plan to determine nanotech risks fails to deliver
2. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Experimental Drug Fails Against Heart Failure
5. NSAID Drug Therapy Fails to Ease Back Pain
6. MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements
7. Steroid Fails to Ease Meningitis in Trials
8. Pharmaceutical market fails pregnant women; and more
9. Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
10. Post-Op Chemo Fails to Boost Survival in Stomach Cancers
11. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... Dermatologists from the Mount ... (AIF), identifying 18 possible melanomas and 46 potential non-melanoma skin cancers (basal cell ... , The Aspen Ideas Festival, which was held from June 25 through July ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... is debuting their brand new website. The website’s goal is to provide patients ... selection of patient tools, including requesting appointments online. , Part of the center’s ...
(Date:7/7/2015)... ... ... The United States Centers for Disease Control and Prevention have awarded Fenway ... Coalition $3.78 million for a five-year HIV prevention partnership that will focus on ... the groups at highest risk of HIV infection in the US. Dubbed ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Quadrino Law Group ... Road, Suite 304, Melville, New York 11747. The new facility is a state ... and rail lines. , Richard Quadrino, the firm's CEO and founder, said, "We are ...
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... the leading global provider of advanced delivery technologies and development solutions for ... an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination ...
Breaking Medicine News(10 mins):Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 2Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 3Health News:More than 700 Screened for Skin Cancer at 2015 Aspen Ideas Festival 4Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2
... that a majority of its Board of Directors ... the Company,s,largest stockholder. During the three-hour meeting, there ... The Board,s desire is to be,responsive and receptive ... what is best to enhance value for all ...
... , , WEDNESDAY, Oct. 10 (HealthDay News) -- When added ... the recurrence of breast cancer by 41 percent in ... study finds. , Those tumors are called "HER2-positive" because ... epidermal growth factor receptor-2 (HER2). , In recent years, ...
... as one of 14 Evidence-based Practice Centers (EPCs) in ... Research and Quality (AHRQ) announced today. , For a ... content and quality of the medical literature on specific ... options, and surgical outcomes for knee replacement. The ...
... Roxane Laboratories, Inc.,announced today the approval ... Oxcarbazepine Tablets, 150mg, 300mg and 600mg by ... is available in bottles of 100 tablets ... wholesalers and pharmacies,nationwide. (Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO ...
... AMN Healthcare Services,Inc. (NYSE: AHS ), the ... its quarterly conference call to discuss third quarter,results on ... The,company expects to issue an earnings news release also ... Time. A live webcast of the call can ...
... (OTC,Bulletin Board: SCOM) ("Sharps" or the "Company"), a ... industry and consumers,today announced that it will release ... October 23, 2007. The release of the ... and webcast beginning at 1:00 p.m. ET. During,the ...
Cached Medicine News:Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 2Health News:Rural/Metro Board of Directors Meets With Accipiter Capital Management 3Health News:Drug a New Weapon Against One Form of Breast Cancer 2Health News:Drug a New Weapon Against One Form of Breast Cancer 3Health News:Vanderbilt Medical Center chosen as Evidence-based Practice Center 2Health News:Vanderbilt Medical Center chosen as Evidence-based Practice Center 3Health News:Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg 2Health News:AMN Healthcare Services To Host Third Quarter Earnings Conference Call on Tuesday, October 30, 2007 2Health News:Sharps Compliance Corp. Announces First Quarter Fiscal Year 2008 Conference Call and Webcast 2
(Date:7/7/2015)... 2015 Accelovance, Inc. (Accelovance), a global ... and General Medicine announced the completion of enrollment ... Heron Therapeutics, Inc. for the Phase 3 trial ... candidate SUSTOL® (granisetron injection, extended release) as part ... 1 receptor antagonist fosaprepitant and IV corticosteroid ...
(Date:7/7/2015)... 2015 Research and ... the "Deciphering Global Major Pharmaceutical Companies, New ... offering. It has been publicly recognized ... in a series of challenges in the recent ... significant overcapacities in small molecule product manufacturing; increasingly ...
(Date:7/7/2015)... 2015  PAREXEL International Corporation (NASDAQ: PRXL ) will ... 2015 on Wednesday, August 5 th , 2015 after the ... on PAREXEL,s website at www.PAREXEL.com and on the ... host a conference call and live webcast at 10:00 a.m. ... the results.  To access the webcast, visit PAREXEL,s website at ...
Breaking Medicine Technology:Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2
... Cancer Patients With Improved Potential,to Battle Their ... --,Arrowhead Research Corporation announced today that two ... Calando,Pharmaceuticals Inc., are presenting data at the ... Meeting. The,presentations summarize the latest research findings ...
... ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics,Inc. (NASDAQ:INGN) ... Los Angeles, California at the Annual Meeting of ... p53 tumor suppressor is one of the most,common ... action is targeted to restoring p53 tumor suppressor,function ...
Cached Medicine Technology:Arrowhead Subsidiaries Insert & Calando Present Data on,Cyclosert Drug Delivery System at AACR Meeting 2Arrowhead Subsidiaries Insert & Calando Present Data on,Cyclosert Drug Delivery System at AACR Meeting 3Arrowhead Subsidiaries Insert & Calando Present Data on,Cyclosert Drug Delivery System at AACR Meeting 4Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference 2Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference 3Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference 4
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: